Abstract 376P
Background
This study aimed to explore the beneficial of intensive nutrition intervention with intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy in the treatment of patients with locally advanced nasopharyngeal carcinoma.
Methods
174 locally advanced nasopharyngeal carcinoma patients (LANPC) receiving radical radiotherapy and concurrent cisplatin-based chemotherapy were enrolled from December, 2000 to December, 2016. Patients were divided into two groups as NI group(which received intensive, individualized nutrition education counseling and oral supplements if required), and UC group (general advice and nutrition booklet, without nutrition education). Propensity score matching was performed to balance the baseline differences between the two groups.
Results
Following one-to-one propensity score matching, survival outcomes for the matched data set indicated that the NI group achieved higher overall survival and failure-free survival (P<0.05) compared with UC. Subgroup analysis revealed that NI was associated with significantly improved OS (Hazard ratio [HR] =1.577, 95% Confidence interval [CI] = 1.055–2.357, P < 0.05) and FFS (HR = 1.53, 95% CI = 1.022–2.29, P<0.05). Additionally, the differences of the main adverse reactions after treatment between the two group were not statistically significant (P>0.05).
Conclusions
Early and intensive NI promoted beneficial outcomes in ameliorating the prognosis in loco-regionally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract